To study the effects of mechanochemically activated (MA) doxorubicin (DOXO) and exposure to electromagnetic fields (40 MHz) on human lung carcinoma A-549 cells.
The antibiotics doxorubicin was applied in two different forms: officinal doxorubicin (OF DOXO) and mechanochemically activated doxorubicin (MA DOXO). MA DOXO was yielded by mechanochemical activation applying friction and impact energy during grinding and consisted of particles with sizes 10 times smaller than OF DOXO.
Six groups were investigated: 1.) control group, 2.) EMF exposure, 3.) OF DOXO application, 4.) MA DOXO application, 5.) OF DOXO application + EMF exposure, and 6.) MA DOXO application + EMF exposure.
Exposure | Parameters |
---|---|
Exposure 1:
40 MHz
Exposure duration:
continuous for 30 min
|
|
Cells were treated in six groups: i) control - no treatment ii) EMF exposure iii) OF DOXO iv) MA DOXO v) OF DOXO + EMF exposure vi) MA DOXO + EMF exposure
Frequency | 40 MHz |
---|---|
Type | |
Exposure duration | continuous for 30 min |
Exposure source |
|
---|---|
Setup | cells exposed in Petri dishes in a round irradiation frame with 3 cm diameter; temperature during exposure: 37°C |
Measurand | Value | Type | Method | Mass | Remarks |
---|---|---|---|---|---|
electric field strength | 27.5 V/m | - | calculated | - | - |
magnetic field strength | 22 A/m | - | - | - | - |
power density | 2 W/cm² | - | - | - | - |
Exposure to 40 MHz electromagnetic fields has a slight influence on the cell proliferation in comparison with the control cells without treatment. Cell survival decreased in the following way: EMF (group 2), OF DOXO application (group 3), MA DOXO application (group4), OF DOXO application + EMF (group 5), and MA DOXO application + EMF (group 6).
The authors concluded that the treatment by mechanochemically activated doxorubicin and drug with EMF showed better targeting of drug in human lung carcinoma A-549 cells outcomes than officinal doxorubicin.
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.